Protective/restorative role of the adipose tissue-derived mesenchymal stem cells on the radioiodine-induced salivary gland damage in rats

Güleser Saylam¹, Ömer Bayır¹, Salih Sinan Gültekin², Ferda Alparslan Pinarlı³, Ünsal Han⁴, Mehmet Hakan Korkmaz⁵, Mehmet Eser Sancaktar⁶, İlkan Tatar⁷, Mustafa Fevzi Sargon⁷, Emel Çadallı Tatar¹

1 University of Health Sciences, Dişkapi Yıldırım Beyazıt Training and Research Hospital, Department of Otolaryngology, Head and Neck Surgery, Ankara, Turkey
2 University of Health Sciences, Dişkapi Yıldırım Beyazıt Training and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey
3 University of Health Sciences, Dişkapi Yıldırım Beyazıt Training and Research Hospital, Department of Stem Cell and Genetic Diagnostic Center, Ankara, Turkey
4 University of Health Sciences, Dişkapi Yıldırım Beyazıt Training and Research Hospital, Department of Pathology, Ankara, Turkey
5 Yıldırım Beyazıt University, Faculty of Medicine, Department of Otolaryngology, Head and Neck Surgery, Ankara, Turkey
6 Ministry of Health, Samsun Training and Reseach Hospital, Department of Otolaryngology, Head and Neck Surgery, Samsun, Turkey
7 Hacettepe University, Faculty of Medicine, Department of Anatomy, Ankara, Turkey

Radiol Oncol 2017; 51(3): 307-316.

Received 21 December 2016
Accepted 7 April 2017

Background. To analyze protective/regenerative effects of adipose tissue-derived mesenchymal stem cells (ADMSC) on ¹³¹I-Radioiodine (RAI)-induced salivary gland damage in rats.

Materials and Methods. Study population consisted of controls (n:6) and study groups (n:54): RAI (Group 1), ADMSC (Group 2), amifostine (Group 3), RAI+amifostine (Group 4), concomitant RAI+ADMSC (Group 5) and RAI+ADMSC after 48 h (Group 6). We used light microscopy (LM), transmission electron microscopy (TEM), and salivary gland scintigraphy (SGS), and analyzed data statistically.

Results. We observed the homing of ADMSC in salivary glands at 1st month on LM. RAI exposure affected necrosis, periductal fibrosis, periductal sclerosis, vascular sclerosis and the total sum score were in a statistically significant manner (P < 0.05). Intragroup comparisons with LM at 1st and 6th months revealed statistically significant improvements in Group 6 (P < 0.05) but not in Groups 4 and 5. Intergroup comparisons of the total score showed that Groups 4 and 5 in 1st month and Group 6 in 6th month had the lowest values. TEM showed vacuolization, edema, and fibrosis at 1st month, and an improvement in damage in 6th month in Groups 5 and 6. SGSs revealed significant differences for the maximum secretion ratio (Smax) (P = 0.01) and the gland-to-background ratio at a maximum count (G/BGmax) (P = 0.01) at 1st month, for G/BGmax (P = 0.01), Smax (P = 0.01) and the time to reach the maximum count over the time to reach the minimum count (Tmax/Tmin) (P = 0.03) at 6th month. 1st and 6th month scans showed differences for Smax and G/BGmax (P = 0.04), but not for Tmax/Tmin (p > 0.05). We observed a significant deterioration in gland function in group 1, whereas, mild to moderate deteriorations were seen in protective treatment groups.

Conclusions. Our results indicated that ADMSC might play a promising role as a protective/regenerative agent against RAI-induced salivary gland dysfunction.

Key words: salivary gland; radioiodine treatment; radiation damage; radiation protection; stem cell transplantation; adipose tissue-derived mesenchymal stem cells
Introduction

Radioiodine (RAI) is used as an effective and common therapy option in hyperthyroidism and thyroid carcinoma; however, it is frequently associated with salivary gland dysfunction. Several types of deterministic side effects may occur immediately after administration (short term, first 96 h), in the next few months (intermediate, until 3 months), or later (long term: >3 months). RAI-induced sialadenitis remains a major clinical problem with a rising incidence of thyroid carcinoma due to early detection of small tumors. Jeong et al. investigated long-term effects of RAI ablation, and reported that 20% of patients had salivary gland dysfunction on scintigraphy.

Salivary glands consist of several cell types, but the glands are mainly differentiated according to serous and mucinous components. Parotid glands are most susceptible to RAI damage because of the dominancy of serous glandular tissue. Xerostomia is rare but an important problem that is mainly due to submandibular gland damage after medical irradiation. Xerostomia, or reduced secretion of saliva, compromises a patient’s quality of life by corrupting oral and dental health, leading to oral infections, dental caries, taste alterations, nocturnal discomfort, and even difficulties of speaking and swallowing. Therefore, prevention or repair of the salivary gland damage is important.

Salivary gland damage is irreversible after development of radiation necrosis, and available treatments can only increase secretion from the remaining surviving tissue. Amifostine is one of the most studied agents used to overcome radiation-related hyposalivation, and its active metabolite (WR-1065) decreases levels of free oxygen radicals. Even though it seems to be a cytoprotective agent, amifostine has many adverse effects, limiting its widespread use. Pilocarpine is used for symptom relief, but none of the medications mentioned above have been advocated for prevention or symptomatic treatment of salivary gland damage. However, to improve the patients’ quality of life and decrease the associated morbidities; new regenerative solutions are needed to obtain functional restoration and repair in affected tissues.

Mesenchymal stem cells (MSCs) isolated from the umbilical cord, adipose tissue, lung tissue, and bone marrow have been used as treatment agents for several diseases due to their capacity of tissue regeneration, trophic support, and modulation of the innate immune response. Homing and engraftment of stem cells have been observed in damaged organs, such as the myocardium and kidney; those stem cells may increase function by reducing the levels of proinflammatory cytokines.

External radiation-induced salivary gland damage has been investigated in some studies. Lombaert et al. showed bone marrow MSCs could travel to damaged salivary glands following mobilization, subsequently inducing the repair processes, which improved gland function and morphology. Jeong et al. investigated the effects of transplantation of human submandibular gland stem cells (hSGSCs) to radiation-damaged rat salivary glands. Their data suggested that mesenchymal-like stem cells could be used for treatment of RAI-induced salivary gland damage.

In this controlled animal study, we investigated the protective/regenerative effects of adipose tissue-derived MSCs (ADMSC) on the RAI-exposed rat salivary glands using structural and functional examinations.

Materials and methods

Study population and design

Sixty female Wistar albino rats weighed 230 – 250 g were used in this study. The animals were kept under standard conditions (temperature: 24 – 26°C; relative humidity: 65 – 70%) in 12-h light/12-h dark cycles, with access to water and seeds ad libitum. RAI was administered at a dose of 74 MBq (2 mCi) by oral route to induce salivary gland damage. ADMSC (i.p; 2×10⁶) and amifostine (i.v; 200 mg/m²) were used as cytoprotective/regenerative agents against the effects of radiation. Our main goal was to determine whether ADMSC had a regenerative effect besides its cytoprotective effect.

The study protocol was approved by Dışkapı Yıldırım Beyazıt Education and Research Hospital’s Animal Ethics Board (2013/38), and instructions of local/international animal research were followed. The national/international regulations of radiation safety and waste disposal for contaminated secretion and materials of radio-exposed rats were also followed.

The study groups were designed as follows:
1. Control group: n = 6,
2. RAI alone group (Group 1, n = 9),
3. ADMSC alone group (Group 2, n = 9),
4. Amifostine alone group (Group 3, n = 9),
5. Simultaneous RAI plus amifostine group (Group 4, n = 9): RAI and amifostine were given at the same time.
5. Simultaneous RAI plus ADMSC group (Group 5, n = 9): RAI and ADMSC were given at the same time.

6. RAI and late ADMSC administration group (Group 6, n = 9). This group was named as “late administration group” since ADMSC was administered 48 h after RAI.

Salivary gland scintigraphy was performed at baseline, and after 1 and 6 months. Three animals in each group were sacrificed at the end of 1st month, and the rest were sacrificed at the end of 6th month of the study. The specimens were examined under the light microscope (LM) and transmission electron microscope (TEM). The study and the control groups were compared in terms of RAI-induced tissue damage. Intergroup comparisons were also done among the study groups.

Preparation of adipose-derived mesenchymal stem cells

Fried and Moustaid-Moussaud’s protocol was used to culture adipose tissue. Adipose tissue explants at a volume of 0.5 cm³ were extracted from the inguinal fat pad of the rats. The tissues were transported from the operating room to the laboratory in a transport buffer (phosphate buffered solution [PBS], 5.5 mM glucose, and 50 g/mL gentamicin), at room temperature. The following procedures were carried out under a laminar flow hood, using sterile equipment. The tissues were transferred to a Petri dish containing 3 mL of PBS, and minced into 10 – 15 mg pieces. The pieces were extensively washed with 10 mL of PBS over a filter containing sterile cotton bandage fabric. Thereafter, they were gently shaken for a short period following transferred to a 25 cm² culture flask, containing 1 mL of PBS. Adipose tissue pieces were cultured within MSC medium (Dulbecco’s Modified Eagle’s Medium – low glucose; Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA), 20% fetal bovine serum (Biological Industries Israel Beit-Haemek Ltd., Kibbutz Beit-Haemek, Israel), 100 U/mL of penicillin, 100 mg/mL of streptomycin (Biological Industries Israel Beit-Haemek Ltd., Kibbutz Beit-Haemek, Israel), and 20 mL/L of L-glutamine. They were incubated at 37°C and in 5% CO₂. Culture medium was changed every three days, and colony-forming unit-fibroblasts were observed at 14 – 16 days with a 70% confluency of the culture plate. The detached cells were subcultured on a standard culture dish, using 0.25% trypsin in 0.02% ethylenediaminetetraacetic acid. After three passages, the cell suspensions were defined with MSC markers including CD11b/c (−), CD45(−), CD90(+), CD44(+), and CD49(+) with the FACS Aria III cell sorter, and stored at −80°C DMEM-LG medium included 10% DMSO and 10% FBS.

To label ADMSC in vitro, 10 μL of BrdU solution (1 mM BrdU in 1 × Dulbecco’s PBS, BD Pharmingen, San Diego, CA, USA) was added for each milliliter of tissue culture medium, and incubated for 2 hours. Cell culture density was 2×10⁶ cells/mL.

To demonstrate the labeled ADMSC, BrdU staining was performed on 6 mm thick slides those were prepared from formalin-fixed, paraffin-embedded tissues, after deparaffinization in xylene to detect BrdU ion. The slides were transferred into 100% and 95% alcohol, then endogenous peroxidase activity was blocked with 3% hydrogen peroxide, and the slides were subsequently rinsed with PBS. Finally, the sections were immunohistochemically stained with a BrdU detection kit (BD Pharmingen) to show the presence of BrdU+ cells.

Light microscopy

The excised salivary gland samples were harvested and fixed in 10% formaldehyde solution. After the paraffinization procedure, tissue sections were stained with hematoxylin and eosin, and a blinded pathologist examined all specimens under the light microscope (Olympus BX-50; Olympus Corporation, Tokyo, Japan). Salivary gland damage was categorized into three stages (0: no damage; 1: mild damage; 2: moderate damage; and 3: severe damage) for each of the following findings: acinar epithelial cells (edema, vacuolization, periacinar inflammation, and necrosis), interstitial space (periductal sclerosis, fibrosis, and mucus leakage), ductal system (ductal ectasia), and vascular system (sclerosis). A total score of histological findings reflected the sum of RAI-induced damage in tissues.

Transmission electron microscopy

Tissue samples were put into 2.5% gluteraldehyde for 24 hours for primary fixation, and they were post-fixed in 1% osmium tetroxide after washing with Sorenson’s phosphate buffer solution (pH: 7.4). In the next step, washing with the same buffer and dehydration in increasing concentrations of alcohol series were done. After dehydration, the tissues were washed with propylene oxide, and embedded in epoxy resin embedding media. Semi-thin (2 μm) and ultra-thin (60 nm) sections of the
obtained from the tissue blocks were cut with an ultramicrotome (LKB Nova, Sweden). Semi-thin sections were stained with methylene blue, and ultra-thin sections were stained with uranyl acetate and lead citrate. Those sections were examined under a light microscope (Nikon Corporation, Tokyo, Japan), and a transmission electron microscope (Jeol JEM 1200 EX (JEOL Ltd., Tokyo, Japan), respectively. The same microscopes were used to photograph the specimens.

**Salivary gland scintigraphy**

A double-headed large-field gamma camera (ECAM, Siemens, IL, USA), equipped with a low-energy, high-resolution collimator was used. After 0.2 – 0.3 ml bolus intravenous injection of 99mTc-pertechnetate (74 MBq) through the tail veins of the rats under anesthesia, dynamic images were collected (120 frames at a rate of 1 frame/20 second) for 40 min with a magnification of 1.23 in a 128 x 128-pixel matrix. For image analysis, oval-shaped regions of interest (ROIs) drawn on the right and left salivary gland regions were used. A ROI on the left supraclavicular area was used for background activity. All ROIs had the same size. The image data were processed, and a time–activity curve (TAC) was generated for each subject using a summarization method including background subtraction and three-point smoothing. Functional assessments of TACs were made for following quantitative parameters: The gland-to-background ratio at a maximum count (G/BGmax) defined the degree of gland parenchymal damage when compared with the background activity since this ratio dropped off due to the parenchymal injury and destruction in a direct manner. The time to reach the maximum count ratio over the time to reach the minimum count (Tmax/Tmin) showed whether the gland activity slowed down due to mostly ductal system damage. It is dependent on the processes of transit in tissue and trans-

### TABLE 1. Histological findings in the salivary glands of the rats. Mean values of salivary gland damage parameters are given. *Details of groups are given below the table

| Site of damage                  | Investigated parameters | Control | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 |
|--------------------------------|-------------------------|---------|---------|---------|---------|---------|---------|---------|
|                                | 1st m 6th m p           | 1st m 6th m p | 1st m 6th m p | 1st m 6th m p | 1st m 6th m p | 1st m 6th m p | 1st m 6th m p | 1st m 6th m p |
| Acinar epithelial cell damage  |                         |         |         |         |         |         |         |         |
| Edema                          | 3.67 5.5 ns             | 6 7.17 ns | 5.67 7.67 0.05 | 5 5.5 ns | 4.33 7 0.02 | 4.33 4.83 ns | 5.67 3 0.02 |
| Vacuolization                  | 4.33 3.5 ns             | 6.67 6.33 ns | 5 7 0.04 | 4.67 4.17 | 4 5.33 ns | 5 3.67 ns | 5.33 2 0.02 |
| Peri acinar inflammation       | 0 0 ns                  | 0.67 0.17 ns | 1.33 0.17 ns | 0.67 0.17 ns | 0 0.17 ns | 0 0.17 ns | 2 0 0.02 |
| Necrosis                       | 0.67 2.33 ns            | 0 1.33 0.04 | 2 0.5 ns | 1.67 1 ns | 0 1 ns | 0.33 0 ns | 0.67 0.17 ns |
| Ductal system damage           |                         |         |         |         |         |         |         |         |
| Ectasia                        | 3 3.33 ns               | 6.33 5.83 ns | 4.33 6 ns | 3.67 2.5 ns | 2.67 4.67 0.01 | 3.67 3.5 ns | 3.33 0.83 0.04 |
| Periductal fibrosis            | 0 0 ns                  | 1 3.33 0.02 | 2.33 3.33 ns | 1 0.33 ns | 2.33 0.02 | 0 1.33 0.01 | 0 0.67 ns |
| Periduktal sclerosis           | 0 0.17 ns               | 2.17 0.02 | 1.33 1.83 ns | 1 0 0.03 | 0.33 ns | 0 0.67 ns | 0 0 ns |
| Periductal mucus leakage       | 1 0.5 ns                | 1 1 ns | 0.67 1.33 ns | 1.33 1 ns | 0.33 0.83 ns | 0.33 0.33 ns | 3 0.5 0.02 |
| Vascular system damage         |                         |         |         |         |         |         |         |         |
| Sclerosis                      | 0 0.17 ns               | 1 4.5 0.01 | 1.67 3.5 ns | 1.33 0.5 ns | 0.67 1.17 ns | 0 1.17 0.01 | 1.67 0.5 ns |
| Total                          | 12.67 15.5 ns           | 22.67 31.83 0.02 | 24.33 31.33 ns | 20.34 15.17 0.05 | 12 22.83 0.02 | 13.66 15.67 ns | 21.67 7.67 0.02 |

Control = healthy subjects; Group 1 = radioiodine; Group 2 = adipose tissue-derived mesenchymal stem cells; Group 3 = amifostine; Group 4 = radioiodine plus amifostine; Group 5 = radioiodine plus adipose tissue-derived mesenchymal stem cells concomitant; Group 6 = radioiodine plus adipose tissue-derived mesenchymal stem cells after 48 h; ns = not significant.
port out of the gland. The maximum secretion ratio (Smax; maximum count - minimum count/maximum count × 100) highlighted secretion capacity of the gland as a percentage.

Statistical analysis

We used SPSS software (version 18.0 for Windows, SPSS Inc., Chicago, USA) for statistical analysis. Kruskal–Wallis test was employed to compare the groups, Mann–Whitney U test was used to analyze the intergroup differences, and Friedman’s test was used to assess the differences in continuous variables.

Results

Light microscopy findings

Table 1 and Figure 1 show the histological findings of the salivary glands in the study groups. Normal salivary gland histology was shown in upper horizontal line from control samples (Figure 1A–C). Homing of ADMSC to RAI-damaged salivary glands and their trans-differentiation into salivary gland cells are seen in Figure 1D–F.

Intragroup comparison of the parameters in the control group showed that none of parameters had statistically significant difference between 1st and 6th months (P > 0.05).

In Group 1, destructive effects of RAI on acinar cells, interstitial space and vascular system over time were demonstrated with presence of necrosis (P = 0.04), periductal fibrosis (P = 0.02), periductal sclerosis (P = 0.02), vascular sclerosis (P = 0.01), and total sum score (P = 0.02). However, the effect of RAI on the ductal system was not significant (P > 0.05). RAI-induced necrosis and increased vacuolization (Figure 1G), periductal fibrosis and inflammation (Figure 1H–I) were shown in Figure 1.

In Group 2, we observed statistically significant differences on acinar epithelial cells with an increase in edema (P = 0.05), vacuolization (P = 0.04) and periductal sclerosis (P = 0.03).

In Group 3, the findings were not related to RAI, and we assumed those findings as insignificant.

In, Amifostine plus RAI (Group 4), Amifostine did not exhibit a sufficient protective effect in intragroup comparison; and yet the damage increased in a statistically significant manner in terms of edema (P = 0.02), ductal ectasia (P = 0.01), periductal fibrosis (P = 0.02) and total sum score (P = 0.02).

Similarly, in the concomitant administration of stem cells plus RAI (Group 5), we determined a statistically significant increase in periductal fibrosis (P = 0.01) and sclerosis (P = 0.01).

ADMSC seemed the most effective in Group 6. There was a statistically significant decrease on 6th month for edema, vacuolisation, periacinar inflammation, periductal mucus leakage (P = 0.02) and ectasia (P = 0.04) compared to the findings obtained.
on month 1. In addition, the sum of all histologic parameters decreased only in Group 6, with late stem cell administration. This improvement in histologic findings were demonstrated in Figure 1J–L.

At 1st month, we found a statistically significantly difference among the groups for periductal fibrosis, sclerosis and the total sum score were \( P < 0.05 \). The differences among the groups were statistically significant for the changes in edema, vacuolisation, necrosis, ectasia, sclerosis, periductal fibrosis, periductal sclerosis, and the total sum score \( P < 0.05 \) at 6th month. We supposed that interstitial space damage and total sum score were good indicators of RAI-induced damage. Total sum scores indicated that histologic improvements were statistically significant in all preservative treatment groups (Groups 4, 5, and 6 vs. Group 1). Total sum score was the smallest in Groups 4 and 5 at 1st month, and in Group 6 at 6th month. We concluded that, although concomitant administrations could be effective in the early phase of RAI-induced damage, late stem cell administration (Group 6) was better for recovery of the functional damage over time when compared to the other administration methods.

**Electron microscopy findings**

TEM demonstrated cellular damage and fibrosis (Figure 2C–D). Intercellular edema and intracellular vacuolization showed cellular damage.

TEM examinations were normal in the control group at 1st and 6th months. We observed large intracellular vacuoles and intense intercellular edema in Group 1. RAI-induced damage was more distinct in samples obtained at 6th month, since the samples exhibited smaller intracellular vacuoles and minimal intercellular edema (Figure 2). The findings of ADMSC-administered group (Group 2) were identical to the findings of the control group. Minimal vacuolization and fibrosis were seen in Group 3, which was administered amifostine alone, but this was reversible, since the 6th month evaluation was normal. We observed vacuolization, edema, and fibrosis due to RAI damage at 1st month in the treatment groups (Groups 4, 5, and 6). The cellular damage and fibrosis improved in both the stem cell plus RAI-administered groups (Groups 5 and 6) at 6th month (Figure 2). However, the RAI damage was not partially reversible with amifostine administration in-group 4. The TEM findings demonstrated the regenerative/restorative effect of ADMSC on RAI-induced salivary gland dysfunction.

**Scintigraphy findings**

The baseline findings were similar for all parameters in all study groups \( P > 0.05 \). RAI groups (Groups 1, 4, 5 and 6) and others (Groups 2 and 3) showed statistically significant differences for Smax \( (P = 0.01) \) and G/BGmax \( (P = 0.01) \), but not for Tmax/Tmin \( (P > 0.05) \) at 1st month. On the other hand, 6th month scans revealed statistically significantly differences between RAI and non-RAI groups for Smax \( (P = 0.01) \), G/BGmax \( (P = 0.01) \) and Tmax/Tmin \( (P = 0.03) \). Combined treatment groups showed significant differences for 1st and
6th month findings for Smax and G/BGmax values ($P = 0.04$), but not for Tmax/Tmin ($p > 0.05$). This might be due to preservation of ductal secretion. RAI-dependent impairment in function at 6th month was the most prominent in Group 1. The measurements for Smax and G/BGmax seemed to be better in concomitant protective administrations with RAI (Groups 4 and 5), but the difference was not statistically significant. Tmax/Tmin ratio was similar among treatment groups with RAI (Groups 4–6). These findings suggested that protective agents could partially overcome functional damage related to RAI (Table 2).

The functional status on a salivary gland scintigraphy can be evaluated easily by a TAC generated from dynamic scintigraphic data. We compared pre- and post-treatment TACs generated from the sequential salivary gland scintigraphies of rats at baseline and at 6th month to observe time-related healing or worsening in the study groups, and to determine protective/regenerative effects of amifostine and ADMSC. Figure 3 depicts the functional change in activity of rat salivary glands over time in RAI and combined treatment groups. A review of the time-sequential findings in Group 1 showed a significant deterioration in function over time with decreased gland uptake and secretion capability (Figure 3A–B). As expected, TACs of two consecutive scans were not different from the baseline in the groups not treated with RAI (Groups 2 and 3). In the analysis of TAC patterns for RAI plus concomitant amifostine and ADMSC groups (Groups 4 and 5) as well as the late ADMSC-administered group (Group 6) mild to moderate deteriorations were seen in function over time in terms of slope of TAC and secretion capability of the gland (Figure 3C–H).

**Discussion**

Well-differentiated thyroid cancer treated with RAI ablation results in high survival rates; however, xerostomia associated with RAI, which is seen in approximately 40–50% of cases, has a severe impact on the quality of life of patients. Various methods have been used to avoid radiation-induced damage to the salivary glands. Amifostine is the only agent approved by United States Food and Drug Administration for salivary gland protection, and its evidence-based protective effects on salivary glands have been shown. However, treatment-associated side effects of this cytoprotective agent including excessive chills, sweating, excessive tearing, dizziness, flushing, voice changes, tremor, nervousness, and diarrhea have limited its use. To our knowledge, this is the first study that showed the favorable effects of ADMSC on RAI-induced salivary gland damage. We administered amifostine in Groups 2 and 3 to compare its effects

| Groups | Baseline | 1st m | 6th m | p | Baseline | 1st m | 6th m | p | Baseline | 1st m | 6th m | p |
|--------|----------|-------|-------|---|----------|-------|-------|---|----------|-------|-------|---|
| Group 1 | 34.80 | 29.58 | 19.72 | 0.04 | 0.07 | 0.08 | 0.14 | 0.05 | 1.63 | 1.38 | 1.30 | 0.04 |
| Group 2 | 34.74 | 34.31 | 34.62 | ns | 0.06 | 0.06 | 0.07 | ns | 1.59 | 1.57 | 1.58 | ns |
| Group 3 | 34.72 | 34.38 | 33.83 | ns | 0.08 | 0.08 | 0.09 | ns | 1.59 | 1.56 | 1.57 | ns |
| Group 4 | 33.07 | 30.30 | 28.88 | 0.04 | 0.08 | 0.08 | 0.09 | ns | 1.57 | 1.49 | 1.44 | 0.04 |
| Group 5 | 33.51 | 32.91 | 28.89 | 0.04 | 0.08 | 0.08 | 0.09 | ns | 1.58 | 1.52 | 1.49 | 0.04 |
| Group 6 | 35.55 | 31.60 | 26.07 | 0.04 | 0.07 | 0.07 | 0.09 | ns | 1.60 | 1.51 | 1.36 | 0.04 |

G/BGmax = Gland-to-background ratio at a maximum count; ns = Not significant; Smax = Maximum secretion ratio; Tmax/Tmin = Ratio of the time to reach the maximum counts to the time to reach the minimum counts.
with the protective effect of the stem cells. We also administered cytoprotective agents alone to rule out their unexpected effects. We compared amifostine and stem cells for their protective effects. We found stem cell administration superior to amifostine, and our findings may provide an alternative option, in absence of frequent side effects.

Stem cells can transform into different cells due to their regenerative capacity. They have recently drawn attraction in regenerative medicine. MSCs are present in mature tissues as multipotent cells, and can differentiate into specific cells that originate from the mesoderm. Mesenchymal cells have self-renewable properties; they can be easily cultured in vitro, and accepted by target tissues. MSCs can be isolated from different tissues such as bone marrow stromal cells, adipose tissue-derived stem cells, and adult skin stromal cells. Some studies on ADMSCs yielded promising results showing that they could be multilineage precursor cells, particularly in regenerative therapies. These cells can be easily obtained from donor tissues with minimal morbidity. Although ADMSCs share similar differentiation capabilities with other MSCs, they have higher isolation yield and proliferation ratios in culture when compared to bone marrow stromal stem cells. ADMSC are not the only precursor of adipocytes; they may also be the progenitor of myocytes, osteoblasts, neuronal cells, chondrocytes, and epithelial cells.

The first effect of stem cell infiltration is the induction of cytokines. Other healing-related benefits of ADMSC administration are anti-inflammatory activity, an ability to accelerate neovascularization, and the capacity to promote restoration of epithelial integrity. Our results indicated that ADMSC administration resulted in a structural/functional recovery, as this preventive effect was associated with its ability to foster cytokine release and anti-inflammatory effects. Stem cells migrate to salivary glands and promote restoration and neovascularization, which results in functional restoration. Histological improvement following ADMSC administration, particularly in the late period may be associated with neovascularization and regeneration capacity of the cells. Our microscopic and scintigraphic findings demonstrated that ADMSCs were homing to salivary glands, and they could protect from permanent tissue damage and irreversible function loss.

Lombaert et al. were first to show the potential use of stem cell transplantation for functional rescue of the salivary glands. They concluded that granulocyte-colony stimulating factor with mobilized bone marrow-derived stem cells might be effective for regenerating and functionally...
restoring externally irradiated salivary glands. Jeong et al. isolated and amplified tissue-specific hSGSCs. They developed a culture system (lasting 4–5 weeks) without any selection. The researchers found that transplantation of hSGSCs to radiation-damaged rat salivary glands rescued the function of the submandibular gland, and improved morphological damage. In another study, the authors systematically administered human ADMSC to mice immediately after local irradiation, and this was repeated once a week for three times. They used salivary flow rates for functional assessment, and immunofluorescence histochemistry for morphological evaluation. The authors suggested that intravenous human ADMSC administration was a candidate therapy for the treatment of radiation-induced salivary gland damage. In light of all those studies, one may say that adult stem cell transplantation may be useful for functional and morphological regeneration of radiation damage in human salivary glands.

Our study differs from the others methodologically, and in terms of its findings in various aspects. Internal instead of external radiation exposure was used to induce salivary gland damage. Salivary gland scintigraphy with 99mTc-pertechnetate was employed for functional evaluation instead of saliva collection or salivary flow rate. In addition, we used TEM to show the healing of damage on ultrastructural level. According to LM findings, initial damage occurs in the interstitial space and vascular system, which results in fibrosis and functional impairment. Sequential scintigraphic findings showed that the parenchyma damage was more than ductal damage. We may conclude that RAI-induced tissue damage is progressive. We observed a decrease in RAI-induced salivary gland damage by administration of amifostine and ADMSC. Concomitant stem cell infiltration had a protective effect; however, the late stem cell administration was restorative. This finding represents evidence of the protective and regenerative effects of ADMSC. Ultrastructural improvements were seen in the stem cell-administered groups in the vascular system damage demonstrated by TEM as vacuole formation and fibrosis. Our scintigraphic findings demonstrated the functional damage of RAI administration, which was prevented with amifostine and stem cell administration.

In this study, we found that the stem cell administration might be more effective than amifostine in rats, concomitant stem cell infiltration could reduce damage, and the late stem cell infiltration could restore tissue more than the other treatments. Our TEM findings indicated that vacuolization, edema, and fibrosis were present at the 1st month evaluation of the preventive treatment groups. One promising result of this study was the improvements seen at 6th month. The ultrastructural healing was better in the stem cell plus RAI-administered groups compared to the amifostine plus RAI groups.

In fact, the patients are administered RAI in hypothyroid state, after thyroidectomy. They have a high concentration of RAI in the body due to especially its slow clearance. In our study, we did not perform thyroidectomy. We administered a higher dose of RAI as given dose per gram of tissue compared to that used in a standard clinical setting. Thus, we may say that we could safely test the effect of protective agents against damage caused by RAI in nonthyroidectomized rats.

Our findings demonstrated that late stem cell administration was more effective than other treatments tested, and all stem cell administrations provided a mild to moderate protection against RAI damage in salivary gland scintigraphy. Therefore, we may suggest a combination of both applications for prevention/restoration of RAI-induced salivary gland damage, with minimal side effects. Further studies are needed to enlighten the effect of stem cell therapy in humans.

We did not investigate releasing factors after stem cell administration; we accepted this as a limitation of our study. We know that stem cells could migrate to all tissues. However, we focused on only salivary gland damage.

In conclusion, radiation-induced hyposalivation remains as a major problem following external radiation or RAI. Since permanent dysfunction decreases the patients’ quality of life, prevention of salivary gland damage and/or restoration of gland functions are important. In the current study, we showed the preventive and restorative capacity of stem cells, with histologic and functional improvements. The underlying key point of histologic and functional restoration could be the ultrastructural improvement of cellular damage. Stem cell infiltration may be a novel and promising method to prevent of xerostomia after radiation. We believe that this valuable approach has a potential to be a standard treatment option in near future after further studies are conducted in humans.

Acknowledgements

This study was financially supported by a grant from Dişkapı Yıldırım Beyazıt Training and
Research Hospital Scientific Research Support Committee.

References

1. Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, et al. Salivary Gland Hypofunction/Xerostomia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 2010; 18: 1039-60. doi:10.1007/s00520-010-0827-8

2. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003; 13: 265-71. doi:10.1089/thy.2003.13.5.265

3. Fard-Esfahani A, Emarni-Ardekan A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun 2014; 35: 808-17. doi:10.1097/NMN.0000000000000132

4. Jeong SY, Kim HW, Lee SW, AhrHC, Lee J. Salivary gland function 5 years after radioiodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms. Thyroid 2013; 23: 609-16. doi:10.1089/thy.2012.0106

5. Bohuslavizki KH, Klutmann S, Jenicke L, Kröger S, Buchert R, Mester T, et al. Radioprotective effect of Ocimum sanctum and amifostine on the salivary gland of rats after therapeutic radioiodine exposure. Cancer Biother Radiopharm 2011; 26: 737-43. doi:10.1089/cbr.2011.1014

6. Joseph LJ, Bhartiya US, Raut YS, Hawaldar RW, Nayak Y, Pawar YP, et al. Radioprotective effect of Osium sanctum and amifostine on the salivary gland of rats after therapeutic radioiodine exposure. Cancer Biother Radiopharm 2011; 26: 737-43. doi:10.1089/cbr.2011.1014

7. Sagowski C, Wenzel S, Merttnerich FU, Kehrl W. Studies on the radioprotective potency of amifostine on salivary glands of rats during fractionated irradiation: acute and late effects. Eur Arch Otorhinolaryngol 2003; 260: 42-7. doi:10.1007/s00405-002-0496-4

8. Pimentel MJ, Filho MM, Araújo M, Gomes DQ, DA Costa LJ. Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Res 2014; 34: 1993-9.

9. Koca G, Gültekin SS, Han U, Kuru S, Demirel K, Korkmaz M. The efficacy of montelukast as a protective agent against 131I-induced salivary gland damage in rats: scintigraphic and histopathological findings. Nucl Med Commun 2013; 34: 507-17. doi:10.1097/MNM.0b013e32835f3edc

10. Hamlar DD, Schuller DE, Gahbauer RA, Buerki RA, Staubus AE, Hall J, et al. Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Laryngoscope 1996; 106: 972-6.

11. Ding DC, Chang YH, Shyu WC, Lin SZ. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant 2015; 24: 339-47. doi:10.1080/09636895.2015.1002213

12. Ramdası S, Sarang S, Viswanathan C. Potential of mesenchymal stem cell based application in cancer. Int J HematoOncol Stem Cell Res 2015; 9: 95-103.

13. Luo CJ, Zhang FJ, Zhang L, Geng YQ, Li GQ, Hong Q, et al. Mesenchymal stem cells ameliorate sepsis-associated acute kidney injury in mice. Shock 2014; 41: 123-29. doi:10.1097/SHK.0000000000000880

14. Weil BR, Manukyan MC, Herrmann JI, Wang Y, Abarbanell AM, Poynter JA, et al. Mesenchymal stem cells attenuate myocardial functional depression and reduce systemic and myocardial inflammation during endotoxemia. Surgery 2010; 148: 448-52. doi:10.1016/j.surg.2010.03.010

15. Lombara et al. Wierenga PK, Kok T, Kampina HH, deHaan G, Coppes RP. Mobilization of bone marrow stem cells by granulocyte colony-stimulating factor ameliorates radiation-induced damage to salivary glands. Clin Cancer Res 2006; 12: 1904-12. doi:10.1158/1078-0432.CCR-05-2381

16. Jeong J, Baek H, Kim YJ, Choi Y, Lee H, Lee E, et al. Human salivary gland stem cells ameliorate hyposalivation of radiation-damaged rat salivary glands. Exp Mol Med 2013; 45: e58. doi:10.1038/em.2013.121

17. Fried SK, Moustaid-Moussa N. Culture of adipose tissue and isolated adipocytes. Methods Mol Biol 2001; 135: 197-212. doi:10.1385/1-59259-231-7:197

18. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39: 1551-4.

19. Solans R, Bosch JA, Galafre P, Porta F, Roselló J, Selva-O’Callaghan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001; 42: 738-43.

20. Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin 2013; 34: 747-54. doi:10.1038/aps.2013.50

21. Horwitz EM, Le Blanc K, Dominici M, Mueller J, Slaper-Cortenbach I, Marinic FC, et al. International Society for Cellular Therapy. Clarification of the nomenclature for MSC. The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7: 393-5. doi:10.1089/cyt.2005.7.393

22. Mayyar B, Ben-David U, Lavon N, Bianco JC, Yakir B, Clark AT, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010; 251-31. doi:10.1016/j.stem.2010.07.017

23. Zák P, Zhu M, Ashjian P, De Ugarte DA, Huang JJ, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13: 4279-95. doi:10.1091/mbc.02-02-0105

24. Salibian AA, Widgerow AG, Abouk M, Evans GR. Stem cells in plastic surgery: a review of current clinical and translational applications. Arch Plast Surg 2013; 40: 666-75. doi:10.5999/aps.2013.40.6.666

25. Zák P, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2011; 7: 211-28. doi:10.1080/174295920100306859

26. Brayfield C, Marra K, Rubin JP. Adipose stem cells for soft tissue regeneration. Handchir Mikrochir Plast Chir 2010; 42: 124-8. doi:10.1055/s-0030-1248269

27. Lim JY, Ra JC, Shin IS, Jang YH, Choi JS, et al. Systematic transplantation of human adipose tissue-derived mesenchymal stem cells for the regeneration of irradiation-induced salivary gland damage. PLoS One 2015; 10: e0137116. doi:10.1371/journal.pone.0137116

28. Gültekin SS, Sahmaran T. The efficacy of patient-dependent practices on exposure rate in patients undergoing iodine-131 ablation. Health Phys 2013; 104: 454-8. doi:10.1097/HP.0b013e3182838583